Kura Oncology: Pay

Kura Oncology paid its 3 named executives $9.3M in total in FY2025 (Dec). CEO Troy E. Wilson, Ph.D., J.D. was paid $4.7M of that.

Pay$100 in the stock at the end of FY20 → $45
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Troy E. Wilson, Ph.D., J.D.President and Chief Executive Officer
FY2025 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
3 years
Brian PowlChief Commercial Officer
FY2025 (Dec)
1 year
Kathleen FordChief Operating Officer
FY2025 (Dec)Not disclosed
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
4 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 8 peers with pay on file was $9.0M. The CEO of Kura Oncology was paid $4.7M, 48% below the median.

  1. 1Cogent Biosciences
  2. 2Revolution Medicines
  3. 3Arcus Biosciences
  4. 4IDEAYA Biosciences
  5. 5Kymera Therapeutics
  6. 6Structure Therapeutics
  7. 7Arvinas
  8. 8Kura Oncology
  9. 9Relay Therapeutics
  10. 10Crinetics PharmaceuticalsNot disclosed
  11. 11Day One BiopharmaceuticalsNot disclosed
  12. 12Iovance BiotherapeuticsNot disclosed
  13. 13Janux TherapeuticsNot disclosed
  14. 14NuvalentNot disclosed
  15. 15SpringWorks TherapeuticsNot disclosed
  16. 16Summit TherapeuticsNot disclosed
  17. 17Syndax PharmaceuticalsNot disclosed
  18. 18XencorNot disclosed
  19. 19iTeos TherapeuticsNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.